Tim Smith

New research presented at ASH 2022 showed survival rate improvements for APL patients through a simplified treatment algorithm designed by the trial investigators.

New research assessed whether the T117S gene variant could be useful as a marker for predicting sickle cell disease patients' might responses to hydroxyurea treatment.

Research into ovarian follicular density in younger female sickle cell disease patients finds no effect from exposure to hydroxyurea.

A study in the Dominican Republic assessed the use of dose escalation of hydroxyurea for children in a single hospital with sickle cell anemia.

Research presented at ASH 2022 examined the ages of onset of ASSC in younger sickle cell disease patients treated with hydroxyurea.

Research indicates the long-term benefits of sustained use of two developed online interventions for younger patients diagnosed with eczema.

Recent research has identified two groups as high risk for developing asthma, with one noted as having early eczema and the other not having the skin condition.

New research suggests lower central foveal thickness fluctuation scores with patients on ranibizumab were associated with the greatest gains in vision.

New research highlights the growing number of claims among all providers, including advanced practice practitioners and non-dermatologists, of Cal/BD foam usage for Medicare beneficiaries.

A discussion with Emily Strouphauer on her team's findings regarding mental health in pediatric psoriasis, as well as her views on helping younger patients facing these issues.

In her HCPLive interview, Emily Strouphauer, BSA, spoke about her team’s recent findings on the association between pediatric psoriasis and anxiety and depression.

In an interview with HCPLive, Dr. Chovatiya spoke about recent FDA approvals for psoriasis treatments, including deucravacitinib, spesolimab, roflumilast, and tapinarof.

During his HCPLive interview, Dr. Eichenfield described the results from the phase 3 TRuE-AD trials testing ruxolitinib for atopic dermatitis, including how the findings might affect treatment for vitiligo or psoriasis.

In a segment from his HCPLive interview, Dr. Lal described the difference between the skin microbiome and the gut microbiome, and their effects on psoriasis.

In an interview segment on HCPLive, Dr. Lal described several treatments approved in 2022 for psoriasis patients such as spesolimab, roflumilast, and tapinarof.

In a recent study, DAMPs were found to play a major role in deteriorating vitiligo conditions by initiating host defenses against signals of danger.

In a recent study, patients with psoriasis and coexistent lupus erythematosus were analyzed regarding their clinical characteristics, condition management, and quality of life.

A population-based cohort study found patients with shingles to have a greater likelihood of developing psoriasis than the control group.

An interview with Dr. Lal on common struggles for psoriasis patients, including associated risks and mental health struggles.

A recent analysis was conducted through a review of 10 studies, examining the connection between psoriasis and depression and anxiety in pediatric patients.

New findings suggest that the use of PCSK9 inhibitors may lead to improved outcomes for patients diagnosed with psoriasis.

A retrospective analysis of 360 individuals identified several malignancy risk factors for plaque psoriasis patients.

An interview in which Dr. Lebwohl assessed the recent phase 3 trial data on itch treatment for psoriasis patients.

Research suggested no significant relationship between peanut sensitivity and AD severity as measured by two scores, although the study was acknowledged to have a smaller population due to pandemic restrictions.

New research on the TNF-alpha inhibitor infliximab as a treatment for PD-1-induced psoriasis demonstrated the treatment’s potential.

A recent analysis indicated the efficacy of 100 or 200 mg of tildrakizumab for moderate-to-severe plaque psoriasis patients.

A Q&A interview with Dr. Simpson regarding the recent INTEGUMENT clinical trial results regarding roflumilast for atopic dermatitis.

An interview on the SDPA 2022 presentation of Dr. Woolery-Lloyd in which she discusses dermatoses affecting patients of color.

A discussion with Dr. Markowitz on her presentation from SDPA 2022, during which she described various gaps in knowledge on skin health and future innovations she hoped to see.

An interview with Dr. Markowitz on her presentation at SDPA 2022 presentation entitled ‘Skin of Color,’ regarding differentiating skin cancer from other conditions.